Loteprednol Etabobate ophthamic suspension 0.5% w/v
Loteprednol Etabobate is synthesized through structural modifications of Prednisolone-related compounds so that it will undergo a predictable transformation to an inactive metabolite. It first bind to the type ll Glucocorticoid receptors.
At molecular level, unbound Glucocorticoids readily cross cell membranes and bind with high affinity to specific cytoplasmic receptors. This binding induces a response by modifying transcription and ultimately protein synthesis to achieve the formation of Antiinflammatory protein that inhibits the enzyme phospolipase A2 which is needed in supply of Arachiodonic acid. The latter is responsible for the formation of the mediators.
Thus inhibits the edema, five in deposition, capilary dilation, leukocyte migration, capilary proliferation, fibroblast proliferation, deposition of collagen and scar formation with inflammation.
Please do not use this drug without consultation of a Registered medical practitioner.
For any emergency always consult your ophthalmologist.
Disclaimer: The information produced here is best of our knowledge and experience and we have tried our best to make it as accurate and up-to-date as possible, but we would like to request that it should not be treated as a substitute for professional advice, diagnosis or treatment.
WE do not take responsibility for any aspect of medicines or treatments. If you have any doubts about your medication, we strongly recommend you to see a doctor immediately